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The Pneumonia Etiology Research for Child Health (PERCH) project is the largest multicountry etiology study
of childhood pneumonia since the Board on Science and Technology in International Development studies of
the 1980s. However, it is not the only recent or ongoing pneumonia etiology study, and even with seven sites, it
cannot capture all epidemiologic settings in the developing world. Funding providers, researchers and
policymakers rely on the best available evidence to strategically plan programs, new research directions and
interventions. We aimed to describe the current landscape of recent pneumonia etiology studies in children
under 5 years of age in the developed and developing world, as ascertained by a literature review of relevant
studies with data since the year 2000 and a survey of researchers in the field of childhood pneumonia. We
collected information on the study population, study design, case definitions, laboratory samples and methods
and identified pathogens. A literature review identified 88 studies with child pneumonia etiology results. As of
June 2010, our survey of researchers identified an additional 65 ongoing and recently completed child
pneumonia etiology studies. This demonstrates the broad existing context into which the PERCH study must
be placed. However, the landscape analysis also reveals a multiplicity of case definitions, levels of clinician
involvement, facility types, specimen collection, and laboratory techniques. It reinforces the need for the
standardization of methods and analyses for present and future pneumonia etiology studies in order to
optimize their cumulative potential to accurately describe the microbial causes of childhood pneumonia.
Each year, approximately 1.6 million children die from
pneumonia [1]. The Pneumonia Etiology Research for
Child Health (PERCH) study is the largest multisite
study of childhood pneumonia since the Board of Sci-
ence and Technology for International Development
(BOSTID) studies were done in the 1980s [2]. The goal
of PERCH is to identify the expected etiologies of
pneumonia in 2015, a time when the burden of the
major causes of bacterial pneumonia in the developing
world, Streptococcus pneumoniae and Haemophilus
influenzae type b (Hib), will likely be significantly re-
duced by widespread introduction and use of conjugate
vaccines. Moreover, PERCH capitalizes upon new mo-
lecular diagnostic techniques that were not available
2 decades ago when the BOSTID studies were carried
out. Another salient difference between PERCH and
the BOSTID studies is that the 7 sites participating
in PERCH will follow a highly standardized protocol,
which includes standardization of enrollment criteria,
specimen collection, and laboratory testing.
Although PERCH is the largest multicountry, child-
hood pneumonia etiology study in developing countries
that has been conducted in the past 2 decades, it is
not the only contemporary pneumonia etiology study,
and cannot capture the entire complexity of all epi-
demiologic settings. In recent years, many developed
and developing country sites have initiated pneumonia
studies that provide etiology data. These studies will
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provide useful complementary data to the PERCH study that will
more fully define and characterize the causes of childhood
pneumonia throughout the world. Yet, because the clinical,
laboratory and statistical analysis approaches of these studies vary
significantly, collating the results of multiple etiology studies will
likely prove challenging. Differences in observed etiology can
arise not only from epidemiologic differences in the sites and
populations studied, which are biologic and epidemiologic at-
tributes relevant to public health decision making, but also from
variability in study design. Consideration of how study design
can affect the results of etiologic studies is crucial to interpreting
such studies in the context of PERCH.
In this paper, we describe the global landscape of sites that are
currently studying pneumonia etiology or have recently studied it
in the developed and developing world as ascertained by a liter-
ature review of studies with data since the year 2000 and a survey
of pneumonia researchers. We did not aim to conduct a sys-
tematic review of the literature or a meta-analysis of study results.
Furthermore, we did not undertake a critical evaluation of the
methods or results from the studies we identified. The purpose of
this project is limited to a landscape analysis to better describe the
breadth of available data on child pneumonia etiology.
METHODS
Literature Review
We conducted a literature review to identify studies with pneu-
monia etiology data. All searches were conducted in June 2010
using the PubMed database and entering search terms that were key
words, MeSH terms, synonyms or truncations. Eight separate
search strategies were conducted. Titles and abstracts were screened
to identify potential studies with pneumonia etiology data in
children under five years old. Eligible studies were abstracted by two
trained abstractors (ZG, YDK). Information abstracted included
study population, study design, case definitions, body fluid sam-
ples, laboratory methods and identified pathogens. The studies
were grouped by category, and summary statistics were described
using Stata version 10 (College Station, TX); no statistical testing
was undertaken on the data.
The inclusion criteria for studies were as follows:
d Study of acute community-acquired pneumonia or acute
lower respiratory tract infection (ALRI).
d Consistent testing for at least one specific etiology in
enrolled patients.
d Enrollment of children,5 years old (can also include older
persons).
d Published between June 2005 and June 2010.
d Data collection from the year 2000 onwards.
d $10 pneumonia/ALRI cases.
d $1 calendar year of surveillance.
d English language.
The exclusion criteria were as follows:
d Exclusive enrollment of bronchiolitis patients.
d Exclusive enrollment of patients with a specific
complication or sequelae of pneumonia (eg, empyema or
parapneumonic effusions).
d Inability to distinguish the etiology of pneumonia cases
from other syndromes (eg, pneumonia cases within a study of
invasive pneumococcal disease).
d Etiology inferred from the upper airway carriage alone.
d Focus only on antibiotic resistance among pneumococcal
isolates.
d Exclusive enrollment of hospital-acquired pneumonia
patients.
Our aim was to identify sites and studies, not publications.
When more than one publication was identified from the
same study, we designated the publication with the most
comprehensive etiology results or methodology details, lon-
gest surveillance period, or the oldest reference, as the ‘‘main
publication.’’ Results from additional publications supple-
mented data when possible. When publications referred to
a particular surveillance network that included sites in mul-
tiple countries, we included a result for the entire surveillance
network and individual results for each country if they were
published separately.
When studies encompassed other disease syndromes other
than pneumonia, such as meningitis and sepsis, we limited
results to pneumonia-specific information when possible.
Clinical trials were only included if they described methods
for etiological diagnoses.
Survey of Pneumonia Researchers
A Web-based survey of researchers who may have conducted
pneumonia etiology research was created to capture infor-
mation regarding unpublished ongoing and recently com-
pleted pneumonia etiology studies among children less than
five years old (Survey Monkey, Palo Alto, California). This
survey was circulated by email on 12 April 2010 to approxi-
mately 5000 pneumonia community members that belonged
to the email address list of PneumoFOCUS [3], a monthly
bulletin providing news about pneumonia, pneumococcal
disease, and pneumococcal vaccines that is written and produced
by our team at Johns Hopkins School of Public Health. We also
contacted researchers who had submitted letters of intent in
response to the PERCH Request for Proposals (RFP) for sites,
researchers at sites selected to be part of the PERCH study,
other known pneumonia surveillance researchers (eg, US Centers
for Disease Control and Prevention’s International Emerging
Infection Program sites) and researchers identified through word
of mouth. We individually contacted researchers to clarify and
confirm certain responses. We followed up by email with known
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pneumonia researchers if they did not respond to our initial
survey request.
The survey included questions about the study population,
study design, case definitions, body fluid samples, laboratory
methods, and identified pathogens. Separate surveys were filled
out for each study if more than one study took place in a given
geographic site. The studies were grouped by category and
summary statistics were described; no statistical testing was
undertaken on the data.
RESULTS
Literature Review
Of 2511 titles and abstracts reviewed, 2311 were excluded
because they did not meet eligibility criteria. The full text of
200 publications was reviewed, and 88 studies with child
pneumonia etiology results were included [4–10] [11–18]
[19–25] [26–30] [31–38] [39–43] [44–51] [52–61] [62–71]
[72–80] [81–91]. Studies ranged in size from 10 to 21 239
pneumonia patients (median 260 patients). We identified
studies in 52 countries (Supplementary Figure 1). Multiple
studies were done in 26 countries. Of these, 8 studies were
identified in the United States; 7 in each of Bangladesh and
India; 6 in Thailand; 5 in South Africa; 4 in each of Brazil,
Philippines and Taiwan; 3 in each of China, Hong Kong,
Kenya, Korea, Japan, Nepal, Nigeria, and Vietnam; and 2 in
each of Argentina, Ethiopia, Finland, Guatemala, Italy, Mex-
ico, Mozambique, Pakistan, Yemen and Zambia. Three studies
(3%) in 5 countries (Brazil, Costa Rica, El Salvador, United
States and Zambia) reported collecting postmortem speci-
mens [29, 31, 69], and 5 (6%) in 10 counties (Bangladesh,
Ecuador, the Gambia, India, Malawi, Mexico, Nigeria,
Pakistan, South Africa and Yemen) reported collecting lung
aspirates [11, 26, 35, 51, 63]. Seven studies used asymptomatic
controls [6, 17, 19, 30, 79, 83, 89]. Additional study characteristics
are summarized in Supplementary Table 1.
Survey
We received 81 responses to the survey. A total of 65 studies were
identified once we removed responses that did not meet our
study criteria. Of the 16 studies excluded from analysis, the
reasons for exclusion were the following: the study was not
a pneumonia etiology study, the study did not include children
less than five years of age or multiple responses were received
describing the same study. Studies ranged in size from 12 to
27 778 pneumonia patients (median 780 patients). Among the
65 pneumonia etiology studies, 41 countries were represented
(Supplementary Figure 1). There were 16 countries that reported
multiple studies. Of these, 6 studies were being conducted in
Bangladesh; 5 in each of Brazil, India and Nepal; 4 in In-
donesia; 3 in each of Kenya, Mozambique, South Africa, the
United States, Australia, Thailand and Spain; and 2 in each of
Jordan, Guatemala, China and Israel. Two studies reported
that they obtained approval to collect postmortem specimens
in their protocols, but neither site had collected any post-
mortem specimens as of March 2011. Additional study
characteristics are reported in Supplementary Table 1.
DISCUSSION
The results of the literature review and survey reveal that
many child pneumonia etiology studies have been and are
taking place throughout the world since the year 2000, which
enable an understanding of PERCH data in the context of
a global landscape of ongoing pneumonia research. The large
quantity and great depth of the available data highlight the
challenges in interpreting various pneumonia etiology studies,
particularly when comparing or combining results. Different
studies employ different case definitions, levels of clinician
involvement, facility types, specimens collected and labora-
tory tests. The use of a common protocol in a multisite study
with broad geographic and epidemiologic representation will
enable inferences to be drawn about the similarities and dif-
ferences from other studies.
Our landscape analysis identified several gaps in the
availability of data regarding childhood pneumonia etiology.
First, there were few studies identified in Latin America
(outside of Brazil, Chile and Argentina), in west and par-
ticularly central Africa, and in the Middle East. No studies
were identified from Russia or China. This gap may be due in
part to our English language inclusion criterion. It is im-
portant to have data from places where child pneumonia
mortality is the highest [92]. South Asia and parts of Africa,
which are regions of the world with the greatest burden of
childhood pneumonia deaths, are well-represented in pneu-
monia etiology studies. Nonetheless, the 5 countries with the
highest burden of child pneumonia deaths—India, Nigeria,
Pakistan, the Democratic Republic of Congo (DRC) and
Afghanistan [1]—are not proportionally represented in our
literature review. Our literature review identified only 7
studies conducted in India, 3 in Nigeria, 2 in Pakistan and
none in the DRC or Afghanistan. Second, there needs to be
more pneumonia etiology studies in countries that have or
are currently introducing both the Hib and pneumococcal
conjugate vaccines. Such studies will help define the new dis-
tribution of pneumonia-causing etiologies in these settings,
which will likely have important implications for diagnosis
and empiric treatment algorithms. Third, there are few studies
that report postmortem results. It is important to understand
the spectrum of etiologies for the most severe cases of pneu-
monia, which will be critical in reducing the still high burden of
childhood pneumonia mortality in the world [93]. Although
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technically and culturally challenging, postmortem studies reveal
a different and complementary picture of etiology that is oth-
erwise underestimated or forgotten. This applies particularly to
tuberculosis, HIV-associated conditions (eg, lymphocytic in-
terstitial pneumonia, Pneumocystis jiroveci (carinii) pneumonia
and cytomegalovirus disease), and to other pathogenic processes
that produce a clinical syndrome that mimics pneumonia (eg,
severe anemia with heart failure or interstitial lung disease).
Variation in the methods employed by different pneu-
monia etiology studies can lead to differences in the identi-
fied etiologies. For example, the case definition used can
influence the distribution of microbial etiologies. Case def-
initions based on radiologic (eg, alveolar consolidation) and
laboratory definitions (eg, left-shift of polymorphonuclear
neutrophils) are likely to identify more bacterial than viral
pneumonia cases. Alternatively, a simple clinical case defi-
nition based on tachypnea (eg, nonsevere pneumonia de-
fined by the Integrated Management of Childhood Illness)
or a definition that included wheeze might lead to the identi-
fication of relatively more viral infections. Given the association
between clinical severity and etiology, the target population and
facility type can also determine the spectrum of etiologies. Thus,
studies in community-based settings, health centers or out-
patient wards may find different ranges of etiologies than
studies in referral hospitals. Age is an influential variable and
studies that exclude older children and focus on infants are
likely to identify more RSV infection, which predominates
in infancy. Neonates, in particular, have a distinct set of
pneumonia pathogens [92, 94].
Other factors that varied across studies were the type of
body fluid specimens collected and the type of laboratory
testing done. Detection of bacterial pneumonia is dependent
to a large extent on blood culture. While a majority of studies
performed blood culture, it is likely that there was consider-
able variation in the sensitivity of the tests, particularly for
Streptococcus pneumoniae, which is a fastidious organism re-
quiring optimal collection and laboratory conditions. There
are other factors that may result in an over-representation of
viral causes of pneumonia. It was notable that the use of PCR
as a diagnostic tool was higher in the studies reported on the
survey (68%) than in those already published in the literature
(46%). As molecular diagnostics become more widely used,
it will be important to disaggregate temporal trends in the
epidemiology of viral pneumonia from trends in laboratory
practice. The findings of PCR testing of nasopharyngeal and
oropharyngeal swabs will need to be interpreted judiciously.
The presence of viral nucleic acids in the pharynx does not
necessarily mean that the virus is acutely causing pneumonia
in the lungs [79, 95]. As PCR use increases, strategies must be
used to help interpret these findings. One such strategy is to
include control children (ie, those without pneumonia) in
whom similar body fluids are collected and tested, which will
allow for improved ability to interpret the PCR results [95].
Our landscape analysis had several limitations. In spite of
employing multiple search strategies, we likely missed identi-
fying some studies. Of note, we only searched the English
language literature and only utilized one literature database
(PubMed). This likely biased our findings by excluding studies
from certain geographic regions such as China, Spanish-
speaking Latin America, Russia and the Middle East where
there may be a substantial body of evidence in local language
publications. We did not search Embase and thus did not
include conference abstracts unless researchers directed us to
specific abstracts. Second, some published studies lacked
sufficient detail to provide information on particular aspects
of the study design that were of interest. Notable missing
data were case definitions, facility types, and eligibility de-
termination. Our survey likely suffered from similar limi-
tations as far as incompleteness of data that was provided for
some studies. Similarly, we only reached out to researchers
who were already identified in the field, which might have led
to gaps in those contacted. Third, not all identified studies
were intended to be pneumonia etiology studies. Several had
other primary objectives, such as to study invasive pneu-
mococcal disease or influenzalike illness, and in that process
identified children with pneumonia. As such, these studies
are by design not comparable to studies that identify mul-
tiple pneumonia pathogens in that their case definitions and
patient mix would likely differ. Finally, we were unable to
verify survey responses.
In conclusion, the review of the literature and the survey of
studies illustrate the context within which the PERCH study
will be interpreted. Pneumonia etiologies are likely to con-
tinue to evolve as more countries introduce Hib and pneu-
mococcal conjugate vaccines. Vaccines for other major causes
of childhood pneumonia such as influenza will likely become
more widely used across the globe or may be successfully
developed (eg, RSV) over the next decade, and therefore, will
further influence the pneumonia burden and remaining eti-
ologies. Improvement in global socioeconomic conditions
will also influence the pneumonia etiologic spectrum in the
future. One of the goals of PERCH is to create a reference
standard for the design, conduct and analysis of pneumonia
etiology studies. This will provide a framework within which
valid between-site comparisons can be drawn and integrated
models can be extended geographically. PERCH will also
contribute to a refinement of the case definition of pneumonia
and provide evidence for the utility of certain body fluid
specimens and laboratory tests. We hope that the definition of
a standard, and the publication of the validation processes
that were undertaken to create that standard, will encourage
investigators to analyze existing studies and design future
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studies with reference to this standard in order to optimize the
epidemiological value of the results.
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